9 hospitals cleared to deliver new CRISPR-based sickle cell treatment

The FDA made a historic approval Dec. 8 when it cleared Casgevy, the nation's first medicine based on CRISPR gene-editing technology, as a treatment for sickle cell disease. Its makers are now working with hospitals to establish a network of specialized treatment centers, and so far nine have been authorized to deliver the treatment. 

Federal regulators approved exagamglogene autotemcel, or exa-cel, marketed as Casgevy, to treat sickle cell disease in patients 12 and older. The one-time treatment is made by Vertex Pharmaceuticals and CRISPR Therapeutics and works by using CRISPR technology to remove the disease-causing gene from a patient's stem cells. 

"The administration of Casgevy requires specialized experience in stem cell transplantation," Vertex said in a news release. "Therefore, Vertex is engaging with experienced hospitals to establish a network of independently operated, authorized treatment centers throughout the U.S. to offer Casgevy to patients." 

Below is a list of hospitals that have been authorized to offer the treatment, with more expected to be added in the coming weeks: 

Boston Medical Center

Children's National Hospital in Washington, D.C.

City of Hope Children's Cancer Center in Los Angeles

Medical City Children's Hospital in Dallas

Methodist Children's Hospital in San Antonio

Nationwide Children's Hospital in Columbus, Ohio

The Children's Hospital at TriStar Centennial in Nashville, Tenn.

The Arthur G. James Cancer Hospital and Solove Research Institute in Columbus, Ohio

UChicago Medicine Comer Children's Hospital

Read more about the treatment and experts' reactions here

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars

/30116360/HR_Homepage_300x250-1

/30116360/HR_Homepage_300x250-2